Mavenir Demonstrates Automated Deployment of Cloud-Native 5G Core at MWC LA
21.10.2019 16:00:00 EEST | Business Wire | Press release
Mobile World Congress: Mavenir, a US-based Network Software Provider, and the industry's only end-to-end cloud-native vendor for CSPs, announced today its 5G Core platform, which includes a comprehensive set of 5G core functions on a containerized cloud-native platform. The decomposition of functions into these modular units provides the operators the flexibility to scale them independently; scalability and flexibility that wasn’t possible with 4G EPC.
Mavenir has invested heavily in developing the 5G Core solution from the ground-up on cloud-native principles that can still be retrofitted on EPCs. The solution encompasses all the major 5G core elements, such as AMF, SMF, UPF, NRF, UDSF, PCF, UDM, UDR, NSSF, AUSF, BSF, N3IWF, SCP, SEPP, and SMSF. All these functions are implemented as micro-services in containers. In addition, Mavenir is also building remaining 5G core functions, NEF, 5G-EIR, NWDAF etc.
The Mavenir 5G Core also combines 4G EPC functionality and offers a ‘Converged Mobile Core’ solution that supports both 4G and 5G subscribers. In addition, the Mavenir 5G Core supports all Standalone (SA) and Non-Standalone (NSA) options. This includes 5G SA Option 2 and Option 5, as well as 5G NSA Option 4 and Option 7. With this comprehensive solution, operators will be able to support in parallel existing 4G subscribers, deploy new commercial grade 5G use cases and reap the benefit of a full array of features and capabilities that 5G promises in early 2020.
Mavenir’s investment in building the 5G Core in a future proof way has generated tremendous interest from service providers around the globe. Mavenir’s 5G Core is being tested at Tier-1 operators in Asia Pacific, Europe and in North America.
“Mavenir is engaged with almost all the leading operators in all regions that are showing eagerness in being early adopters and taking advantage of a truly cloud-native microservices-based 5G Core solution,” said Pardeep Kohli, Mavenir’s President and CEO. “This 5G Core allows mobile operators to move directly to next generation technology instead of investing in older 4G elements and Mavenir has the resources and plans to continue to develop the entire scope of 5G Core portfolio.”
Added Kohli, “This 5G Core solution, along with Mavenir’s recent announcement of 4G/5G OpenRAN, affirms the fact that Mavenir is a truly end-to-end network provider.”
At Mobile World Congress Los Angeles, Mavenir will be showcasing the deployment of 6 different 5GC CNFs. Mavenir’s 5G Core solution will be demonstrated along with automation to deploy the Container as a Service (CaaS) and Platform as a Service (PaaS) based on Cloud Native Computing Foundation (CNCF) open source components. To complement the leading edge 5G Core solution, Mavenir has developed automation of deployment and configuration of the CaaS, PaaS and 5G Core Container Network Functions (CNFs).
Request a meeting or learn more here.
About Mavenir:
Mavenir is the industry's only end-to-end, cloud-native network software provider. Focused on accelerating software network transformation and redefining network economics for Communications Service Providers (CSPs) by offering a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN – Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging industry-leading firsts in VoLTE, VoWiFi, Advanced Messaging (RCS), Multi-ID, vEPC, and open RAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 130 countries, which serve over 50% of the world’s subscribers.
We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. Learn more at www.mavenir.com
Mavenir, the M logo, and CloudRange are trademarks owned by Mavenir Systems, Inc.
Copyright © 2019 Mavenir Systems, Inc. All Rights Reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191021005027/en/
Contact information
Maryvonne Tubb
Mavenir PR
NA-Loren Guertin
MatterNow
EMEA-Kevin Taylor
GlobalResultsPR
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 16:37:00 EEST | Press release
Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent and high-quality drafts and featuring SpeechLive's built-in integrations with leading case management platforms such as Actionstep, Clio, iManage and NetDocuments, supporting existing billing, e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom